OTCMKTS:PHGUF - Pharming Group Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.45 -0.06 (-3.97 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$1.51
Today's Range$1.45 - $1.45
52-Week Range$0.4680 - $1.96
Volume300 shs
Average Volume4,940 shs
Market Capitalization$914.84 million
P/E Ratio-8.06
Dividend YieldN/A
Pharming Group logoPharming Group N.V., a specialty pharmaceutical company, develops and produces human therapeutic proteins for the treatment of rare diseases and unmet medical needs. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of angioedema attacks in patients with acute hereditary angioedema (HAE) in Europe, the United States, Israel, European Union countries, Norway, Iceland, and Liechtenstein. It also engages in the development of recombinant human C1 inhibitor for treating HAE attacks; and recombinant human factor VIII (rhFVIII), a natural human blood clotting factor for treating haemophilia A. The company has a strategic collaboration with Shanghai Institute of Pharmaceutical Industry for the development, manufacture, and commercialization of new products based on the Pharming technology platform; and a partnership agreement with the China State Institute of Pharmaceutical Industry for the development of rhFVIII for the treatment of Haemophilia A. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Receive PHGUF News and Ratings via Email

Sign-up to receive the latest news and ratings for PHGUF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Tobacco products


Debt-to-Equity Ratio3.14
Current Ratio1.51
Quick Ratio1.19


Trailing P/E Ratio-8.06
Forward P/E Ratio72.50
P/E GrowthN/A

Sales & Book Value

Annual Sales$101.24 million
Price / Sales8.29
Cash FlowN/A
Price / CashN/A
Book Value$0.04 per share
Price / Book36.25


EPS (Most Recent Fiscal Year)($0.18)
Net Income$-90,370,000.00
Net Margins-66.86%
Return on Equity-676.88%
Return on Assets-49.50%


Outstanding Shares579,020,000
Market Cap$914.84 million

Pharming Group (OTCMKTS:PHGUF) Frequently Asked Questions

What is Pharming Group's stock symbol?

Pharming Group trades on the OTCMKTS under the ticker symbol "PHGUF."

How were Pharming Group's earnings last quarter?

Pharming Group (OTCMKTS:PHGUF) released its earnings results on Thursday, March, 5th. The biotechnology company reported $0.05 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.04 by $0.01. Pharming Group had a negative return on equity of 676.88% and a negative net margin of 66.86%. View Pharming Group's Earnings History.

When is Pharming Group's next earnings date?

Pharming Group is scheduled to release their next quarterly earnings announcement on Thursday, August, 23rd 2018. View Earnings Estimates for Pharming Group.

What is the consensus analysts' recommendation for Pharming Group?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pharming Group in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pharming Group.

Who are some of Pharming Group's key competitors?

Who are Pharming Group's key executives?

Pharming Group's management team includes the folowing people:
  • Dr. Sijmen de Vries, Chairman of Management Board & CEO (Age 59)
  • Mr. Robin Wright, Chief Financial Officer and Member of Management Board (Age 54)
  • Dr. Bruno M. L. Giannetti M.D., Ph.D., Chief Operations Officer and Member of Management Board (Age 66)
  • Dr. Pericles Calias Ph.D., Chief Scientific Officer
  • Mr. Paul Th. Janssen MA MBA MSc, VP of Marketing & Sales (Age 49)

Has Pharming Group been receiving favorable news coverage?

News articles about PHGUF stock have been trending somewhat positive on Saturday, according to Accern. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pharming Group earned a coverage optimism score of 0.11 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 47.34 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Pharming Group.

How do I buy shares of Pharming Group?

Shares of PHGUF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pharming Group's stock price today?

One share of PHGUF stock can currently be purchased for approximately $1.45.

How big of a company is Pharming Group?

Pharming Group has a market capitalization of $914.84 million and generates $101.24 million in revenue each year. The biotechnology company earns $-90,370,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Pharming Group employs 94 workers across the globe.

How can I contact Pharming Group?

Pharming Group's mailing address is Darwinweg 24, Leiden P7, 2333 CR. The biotechnology company can be reached via phone at 31-71-524-7400 or via email at [email protected]

MarketBeat Community Rating for Pharming Group (OTCMKTS PHGUF)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  87 (Vote Outperform)
Underperform Votes:  118 (Vote Underperform)
Total Votes:  205
MarketBeat's community ratings are surveys of what our community members think about Pharming Group and other stocks. Vote "Outperform" if you believe PHGUF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PHGUF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.